Literature DB >> 23302579

Stability and compatibility of vancomycin for administration by continuous infusion.

Violeta Raverdy1, Els Ampe, Jean-Daniel Hecq, Paul M Tulkens.   

Abstract

BACKGROUND: Vancomycin is increasingly used by continuous infusion, but few specific data are available about stability under practical conditions of preparation and use, and compatibility with other intravenous drugs commonly used in the routine hospital setting.
METHODS: Vancomycin stability [defined as recovery ≥ 93% of the original content (validated HPLC assay)] was examined throughout the whole process of centralized preparation, storage and use in the ward by infusion for up to 48 h, with allowances for deviations from recommended practice [exposure to high temperature; use of concentrated solutions (up to 83 g/L)]. Compatibility was assessed by mimicking co-administration in a single line via Y-shaped connectors with contact of 1 h at 25°C, followed by visual inspection (professional viewer), detection of particulate matter (particle analyser) and HPLC assay of vancomycin.
RESULTS: Vancomycin was stable during the whole process and also during 72 h exposure of concentrated solutions at temperatures up to 37°C. Major incompatibilities were seen with β-lactams (temocillin, piperacillin/tazobactam, ceftazidime, imipenem, cefepime and flucloxacillin) and moxifloxacin, but not with ciprofloxacin, aminoglycosides and macrolides. Propofol, valproic acid, phenytoin, theophylline, methylprednisolone and furosemide were also incompatible, whereas ketamine, sufentanil, midazolam, morphine, piritramide, nicardipine, urapidil, dopamine, dobutamine and adrenaline were compatible. No effect or incompatibility with N-acetyl-cysteine or amino acid solutions was detected.
CONCLUSIONS: Centralized preparation of vancomycin and its use by continuous infusion in wards is safe concerning stability, but careful attention must be paid to incompatibilities. Several drugs (including all β-lactams) require distinct intravenous lines or appropriate procedures to avoid undue contact.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23302579     DOI: 10.1093/jac/dks510

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

1.  Design and prospective validation of a dosing instrument for continuous infusion of vancomycin: a within-population approach.

Authors:  Erik M van Maarseveen; Annemien Bouma; Daniel J Touw; Cees Neef; Arthur R H van Zanten
Journal:  Eur J Clin Pharmacol       Date:  2014-08-30       Impact factor: 2.953

2.  Evaluation of the stability of vancomycin solutions at concentrations used in clinical services.

Authors:  Morgane Masse; Stéphanie Genay; Anthony Martin Mena; Natacha Carta; Damien Lannoy; Christine Barthélémy; Bertrand Décaudin; Pascal Odou
Journal:  Eur J Hosp Pharm       Date:  2020-02-05

Review 3.  Optimizing the Clinical Use of Vancomycin.

Authors:  Rocío Álvarez; Luis E López Cortés; José Molina; José M Cisneros; Jerónimo Pachón
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

4.  Endothelial Cell Toxicity of Vancomycin Infusion Combined with Other Antibiotics.

Authors:  Maryline Drouet; Feng Chai; Christine Barthélémy; Gilles Lebuffe; Bertrand Debaene; Bertrand Décaudin; Pascal Odou
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

5.  Influence of vancomycin infusion methods on endothelial cell toxicity.

Authors:  Maryline Drouet; Feng Chai; Christine Barthélémy; Gilles Lebuffe; Bertrand Debaene; Bertrand Décaudin; Pascal Odou
Journal:  Antimicrob Agents Chemother       Date:  2014-11-24       Impact factor: 5.191

6.  Chemical and Physical Stability of an Admixture Containing Cefepime and Vancomycin in Lactated Ringer Solution.

Authors:  Pegah Shakeraneh; Risako Robinson; Wesley D Kufel; L Nathan Tumey; Samantha R Benjamin; Christopher D Miller; William Darko; Luke A Probst; Robert W Seabury
Journal:  Hosp Pharm       Date:  2020-01-23

7.  Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.

Authors:  Kevin Meyer; Maressa Santarossa; Larry H Danziger; Eric Wenzler
Journal:  Hosp Pharm       Date:  2017-03

8.  Effects of antibiotic physicochemical properties on their release kinetics from biodegradable polymer microparticles.

Authors:  Sarita R Shah; Allan M Henslee; Patrick P Spicer; Shun Yokota; Sophia Petrichenko; Sachin Allahabadi; George N Bennett; Mark E Wong; F Kurtis Kasper; Antonios G Mikos
Journal:  Pharm Res       Date:  2014-05-30       Impact factor: 4.200

Review 9.  Continuous Infusion Vancomycin in Pediatric Patients: A Critical Review of the Evidence.

Authors:  Heather L Girand
Journal:  J Pediatr Pharmacol Ther       Date:  2020

Review 10.  Vancomycin Dosing and Monitoring: Critical Evaluation of the Current Practice.

Authors:  Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-06       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.